Literature DB >> 20304513

Is (18)F-FDG a surrogate tracer to measure tumor hypoxia? Comparison with the hypoxic tracer (14)C-EF3 in animal tumor models.

Nicolas Christian1, Stéphanie Deheneffe, Anne Bol, Marc De Bast, Daniel Labar, John A Lee, Vincent Grégoire.   

Abstract

INTRODUCTION: Fluorodeoxyglucose (FDG) has been reported as a surrogate tracer to measure tumor hypoxia with positron emission tomography (PET). The hypothesis is that there is an increased uptake of FDG under hypoxic conditions secondary to enhanced glycolysis, compensating the hypoxia-induced loss of cellular energy production. Several studies have already addressed this issue, some with conflicting results. This study aimed to compare the tracers (14)C-EF3 and (18)F-FDG to detect hypoxia in mouse tumor models.
MATERIALS AND METHODS: C3H, tumor-bearing mice (FSAII and SCCVII tumors) were injected iv with (14)C-EF3, and 1h later with (18)F-FDG. Using a specifically designed immobilization device with fiducial markers, PET (Mosaic®, Philips) images were acquired 1h after the FDG injection. After imaging, the device containing mouse was frozen, transversally sliced and imaged with autoradiography (AR) (FLA-5100, Fujifilm) to obtain high resolution images of the (18)F-FDG distribution within the tumor area. After a 48-h delay allowing for (18)F decay a second AR was performed to image (14)C-EF3 distribution. AR images were aligned to reconstruct the full 3D tumor volume, and were compared with the PET images. Image segmentation with threshold-based methods was applied on both AR and PET images to derive various tracer activity volumes. The matching index DSI (dice similarity index) was then computed. The comparison was performed under normoxic (ambient air, FSAII: n=4, SCCVII, n=5) and under hypoxic conditions (10% O(2) breathing, SCCVII: n=4).
RESULTS: On AR, under both ambient air and hypoxic conditions, there was a decreasing similarity between (14)C-EF3 and FDG with higher activity sub-volumes. Under normoxic conditions, when comparing the 10% of tumor voxels with the highest (18)F-FDG or (14)C-EF3 activity, a DSI of 0.24 and 0.20 was found for FSAII and SCCVII, respectively. Under hypoxic conditions, a DSI of 0.36 was observed for SCCVII tumors. When comparing the (14)C-EF3 distribution in AR with the corresponding (18)F-FDG-PET images, the DSI reached values of 0.26, 0.22 and 0.21 for FSAII and SCCVII under normoxia and SCCVII under hypoxia, respectively.
CONCLUSION: This study showed that FDG is not a good surrogate tracer for tumor hypoxia under either ambient or hypoxic conditions. Only specific hypoxia tracers should be used to measure tumor hypoxia.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20304513     DOI: 10.1016/j.radonc.2010.02.020

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  12 in total

1.  Increased glucose metabolism by FDG-PET correlates with reduced tumor angiogenesis in oral squamous cell carcinoma.

Authors:  Mikiko Nakamura; Yoshimasa Kitagawa; Yutaka Yamazaki; Hironobu Hata; Motoko Kotsuji; Yasuhisa Fujibayashi; Hidehiko Okazawa; Yoshiharu Yonekura; Kazuo Sano
Journal:  Odontology       Date:  2011-05-13       Impact factor: 2.634

Review 2.  Imaging hypoxia to improve radiotherapy outcome.

Authors:  Michael R Horsman; Lise Saksø Mortensen; Jørgen B Petersen; Morten Busk; Jens Overgaard
Journal:  Nat Rev Clin Oncol       Date:  2012-11-13       Impact factor: 66.675

Review 3.  Molecular imaging-based dose painting: a novel paradigm for radiation therapy prescription.

Authors:  Søren M Bentzen; Vincent Gregoire
Journal:  Semin Radiat Oncol       Date:  2011-04       Impact factor: 5.934

Review 4.  PET-CT for radiotherapy treatment planning and response monitoring in solid tumors.

Authors:  Johan Bussink; Johannes H A M Kaanders; Winette T A van der Graaf; Wim J G Oyen
Journal:  Nat Rev Clin Oncol       Date:  2011-01-25       Impact factor: 66.675

Review 5.  PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence.

Authors:  Egesta Lopci; Ilaria Grassi; Arturo Chiti; Cristina Nanni; Gianfranco Cicoria; Luca Toschi; Cristina Fonti; Filippo Lodi; Sandro Mattioli; Stefano Fanti
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-06-07

Review 6.  Validation of functional imaging as a biomarker for radiation treatment response.

Authors:  C Jentsch; B Beuthien-Baumann; E G C Troost; G Shakirin
Journal:  Br J Radiol       Date:  2015-05-29       Impact factor: 3.039

7.  Dose painting based on tumor uptake of Cu-ATSM and FDG: a comparative study.

Authors:  Malene Martini Clausen; Anders Elias Hansen; Michael Lundemann; Christian Hollensen; Tobias Pommer; Per Munck Af Rosenschöld; Annemarie Thuri Kristensen; Andreas Kjær; Fintan J McEvoy; Svend Aage Engelholm
Journal:  Radiat Oncol       Date:  2014-10-16       Impact factor: 3.481

8.  Assessment of tumour hypoxia, proliferation and glucose metabolism in head and neck cancer before and during treatment.

Authors:  Joanna Kazmierska; Witold Cholewinski; Tomasz Piotrowski; Anna Sowinska; Bartosz Bak; Paulina Cegła; Julian Malicki
Journal:  Br J Radiol       Date:  2020-01-02       Impact factor: 3.039

9.  Dose escalation to high-risk sub-volumes based on non-invasive imaging of hypoxia and glycolytic activity in canine solid tumors: a feasibility study.

Authors:  Malene M Clausen; Anders E Hansen; Per Munck Af Rosenschold; Andreas Kjaer; Annemarie T Kristensen; Fintan J McEvoy; Svend A Engelholm
Journal:  Radiat Oncol       Date:  2013-11-07       Impact factor: 3.481

10.  Micro Regional Heterogeneity of 64Cu-ATSM and 18F-FDG Uptake in Canine Soft Tissue Sarcomas: Relation to Cell Proliferation, Hypoxia and Glycolysis.

Authors:  Kamilla Westarp Zornhagen; Anders E Hansen; Jytte Oxboel; Andreas E Clemmensen; Henrik H El Ali; Annemarie T Kristensen; Andreas Kjær
Journal:  PLoS One       Date:  2015-10-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.